Advanced Drug Delivery Devices

A special issue of Micromachines (ISSN 2072-666X). This special issue belongs to the section "B:Biology and Biomedicine".

Deadline for manuscript submissions: closed (15 March 2021) | Viewed by 9213

Special Issue Editor


E-Mail Website
Guest Editor
Graduate School of Engineering, Graduate School of Biomedical Engineering, Tohoku University, Sendai 980-8579, Japan
Interests: micro/nanodevice; biomedical engineering/biological materials studies; nano materials/nano bioscience
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Recent advances in biomaterials and micro/nanotechnology have led to the improvement of drug delivery devices, which are specialized tools for the delivery of a drug via a specific route of administration. Yet, such devices face some technological hurdles to fully achieve their potential. Novel drug delivery devices aim to deliver drugs in a spatiotemporal- and dosage-controlled manner, with a goal to address unmet medical needs, including effective delivery of biopharmaceuticals, targeted delivery to areas protected by barriers, localized delivery of potent drugs, and improved patient compliance. This Special Issue seeks to showcase research papers, short communications, and review articles that focus on (1) reservoir-based drug delivery devices, (2) implantable or transdermal drug delivery devices in a minimally invasive way, (3) devices to encapsulate therapeutic cells, and (4) novel materials and techniques related to drug delivery devices.

Prof. Hirokazu Kaji
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Micromachines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomaterials
  • cell encapsulation
  • controlled release
  • implants
  • MEMS
  • microfluidics
  • micro/nanotechnology
  • microneedles
  • minimally invasive

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 42768 KiB  
Article
Shape Memory Alloy Capsule Micropump for Drug Delivery Applications
by Youssef Kotb, Islam Elgamal and Mohamed Serry
Micromachines 2021, 12(5), 520; https://doi.org/10.3390/mi12050520 - 6 May 2021
Cited by 19 | Viewed by 3590
Abstract
We introduce a shape memory alloy (SMA) actuated micropump optimized for drug delivery applications. The proposed novel design integrates a built-in replaceable drug reservoir within the pump package forming a self-contained preloaded capsule pump with an overall pump volume of 424.7 μL. The [...] Read more.
We introduce a shape memory alloy (SMA) actuated micropump optimized for drug delivery applications. The proposed novel design integrates a built-in replaceable drug reservoir within the pump package forming a self-contained preloaded capsule pump with an overall pump volume of 424.7 μL. The new design results in a compact, simple, and inexpensive micropump and reduces the probability of contamination with attained almost zero dead volume values. The pump consists of NiTi-alloy SMA wires coiled on a flexible polymeric enclosure and actuated by joule heating. Unlike diaphragm and peristaltic SMA micropump designs that actuate transversely, our design is actuated longitudinally along the direction of the highest mechanical compliance resulting in large strokes in the order of 5.6 mm at 27% deflection ratio, actuation speed up to 11 mm/s, and static head pressures up to 14 kPa (105 mmHg) at 7.1 W input power; thus, high throughputs exceeding 2524 μL/min under free convention conditions could be achieved. A model was developed to optimize the pump’s geometrical parameters and the enclosure material. The model concluded that low stiffness enclosure material combined with thinner SMA wire diameter would result in the maximum deflection at the lowest power rating. To prove its viability for drug delivery applications, the pump was operated at a constant discharge volume at a relatively constant static head pressure. Furthermore, a design of bicuspid-inspired polymeric check-valves is presented and integrated onto the pump to regulate the flow. Since the built-in reservoir is replaceable, the pump capsule can be reused multiple times and for multiple drug types. Full article
(This article belongs to the Special Issue Advanced Drug Delivery Devices)
Show Figures

Figure 1

12 pages, 4095 KiB  
Article
A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
by Hideto Kojima, Bibek Raut, Li-Jiun Chen, Nobuhiro Nagai, Toshiaki Abe and Hirokazu Kaji
Micromachines 2020, 11(4), 436; https://doi.org/10.3390/mi11040436 - 21 Apr 2020
Cited by 13 | Viewed by 5091
Abstract
Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on [...] Read more.
Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant. Full article
(This article belongs to the Special Issue Advanced Drug Delivery Devices)
Show Figures

Figure 1

Back to TopTop